See the DrugPatentWatch profile for Ivacaftor
When does ivacaftor lose exclusivity?
Exact dates depend on which “exclusivity” you mean: patent expiry, regulatory exclusivity (for example, New Chemical Entity/marketing exclusivity), and any additional periods added by jurisdiction-specific rules. Ivacaftor’s timeline also varies by market (U.S., EU, U.K., etc.) and by product presentation (for example, tablets vs. granules).
If you tell me the country (or the specific product name/strength), I can narrow the answer to the relevant exclusivity types and the most likely end date.
What kinds of exclusivity can still block generic ivacaftor?
Even after a key compound patent ends, generic or competing products may still be delayed by:
- Other patents covering specific formulations, dosing regimens, or combinations
- Pediatric-related exclusivity extensions (jurisdiction-dependent)
- Regulatory exclusivity periods tied to first approval or specific indications
Because “loss of exclusivity” is often used loosely, the practical question is whether there is still an active patent or regulatory protection that prevents an approved generic/biosimilar or a label expansion competitor from marketing.
How does “loss of exclusivity” relate to generics and launch timing?
For small-molecule drugs like ivacaftor, the market typically opens when the last relevant protection expires or is overcome (for example, by patent challenges or licensing). In practice, launch timing is often tied to:
- Patent expiry dates (and any court stays)
- Regulatory approval pathway timing once the drug is eligible
- Whether a competitor can use a right-of-reference or establish bioequivalence without relying on protected claims
So the first “loss” in legal terms may not immediately equal the first day a generic appears, depending on filings and regulatory readiness.
Are there key patent challenges or lawsuits around ivacaftor exclusivity?
If patents are expected to expire but competitors want earlier entry, litigation and settlement agreements can shift the effective launch window. The exact situation depends on the patent family and the parties involved in each jurisdiction.
Share the market (e.g., U.S. AND “ivacaftor tablets” vs. EU) and I can pinpoint the relevant patent/exclusivity landscape more precisely.
What’s the difference between indication exclusivity and product exclusivity?
Ivacaftor may have exclusivity protections tied to:
- The original approval (product-level/regulatory exclusivity)
- Specific indications or additional labeled uses (indication-level protection)
A competitor may be able to enter for some indications earlier than others if only part of the exclusivity is still in force.
If exclusivity expires, what usually happens to price and availability?
Once ivacaftor is no longer protected in a given market, you typically see:
- One or more generics or alternative branded competitors entering
- Price competition and coverage changes by payers
- Potential substitution restrictions depending on patient population and local formularies
Actual outcomes depend on how many competitors enter and how quickly they gain formulary access.
What do patients and payers usually ask about?
Common questions around “loss of exclusivity” include:
- Will switching from the originator to a generic affect effectiveness or side effects?
- Will insurance coverage change, and how soon?
- Are there dosing-formulation differences (tablets vs. granules) that affect who can switch?
If you share the patient context (age range, dose form, country), I can focus on the practical switching concerns.
Quick clarification so I can give a precise date
Which one do you need?
1) U.S. or EU/UK (or another country)?
2) Patent expiry date, regulatory exclusivity end, or “generic actually launches” date?
3) Ivacaftor alone (Kalydeco) or a specific combination product/strength?
Reply with those details and I’ll provide the most accurate exclusivity-loss timeline for the relevant jurisdiction and product.